{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:15:14Z","timestamp":1789964114321,"version":"4.0.1"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T00:00:00Z","timestamp":1393545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089080","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T21:41:17Z","timestamp":1393623677000},"page":"e89080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia"],"prefix":"10.1371","volume":"9","author":[{"given":"Seiichi","family":"Okabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"CL Sawyers","year":"1992","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190 (BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"RL Ilaria Jr","year":"1996","journal-title":"J Biol Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"H Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance,","volume":"145","author":"HM Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"FP Santos","year":"2011","journal-title":"Cancer J"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"E Jabbour","year":"2011","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"T O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"JE Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.163.163","article-title":"A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial","volume":"120","author":"JE Cortes","year":"2012","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/biot.200900032","article-title":"Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics","volume":"4","author":"RB Selvi","year":"2009","journal-title":"Biotechnol J"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"MA Glozak","year":"2007","journal-title":"Oncogene"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","article-title":"Clinical studies of histone deacetylase inhibitors","volume":"15","author":"HM Prince","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"S Kimura","year":"2005","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood-2013-04-494773","article-title":"Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells","volume":"122","author":"S Okabe","year":"2013","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00277-010-0998-x","article-title":"Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells","volume":"89","author":"S Okabe","year":"2010","journal-title":"Ann Hematol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbrc.2013.05.022","article-title":"Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells","volume":"435","author":"S Okabe","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2867-13-32","article-title":"Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells","volume":"13","author":"S Okabe","year":"2013","journal-title":"Cancer Cell Int"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/scd.2007.9994","article-title":"Depsipeptide (FK228) preferentially induces apoptosis in BCR\/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis","volume":"16","author":"S Okabe","year":"2007","journal-title":"Stem Cells Dev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"J Tan","year":"2010","journal-title":"J Hematol Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"KM VanderMolen","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1158\/0008-5472.CAN-08-0644","article-title":"Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion","volume":"68","author":"Y Yang","year":"2008","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"AJ Wilson","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V96.6.2269","article-title":"BCR-ABL activates transcription of the BCL-X gene through STAT5","volume":"96","author":"F Gesbert","year":"2000","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5826","DOI":"10.1038\/sj.onc.1204549","article-title":"Cooperative and redundant effects of STAT5 and Ras signaling in BCR\/ABL transformed hematopoietic cells","volume":"20","author":"RR Hoover","year":"2001","journal-title":"Oncogene"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.12382","article-title":"Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study","volume":"162","author":"NP Shah","year":"2013","journal-title":"Br J Haematol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T22:15:02Z","timestamp":1597529702000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089080"}},"subtitle":[],"editor":[{"given":"Ivan Cruz","family":"Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089080","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}